The United Kingdom’s National Health Service (NHS) announced a significant shift on Tuesday in its approach to treating children suffering from gender dysphoria. Moving forward, the agency will substantially limit the prescribing of puberty blockers to children.
The policy change is rooted in concerns over the lack of long-term evidence that “gender-affirming care” treatments are safe and effective for minors. The decision represents a significant moment in the ongoing debate over how to treat children who are confused about their gender.
England’s National Health Service banned the use of puberty blockers for children seeking treatment for gender dysphoria, citing limited research.
Puberty blockers, or gonadotropin-releasing hormone analogues (GnRHa), is a class of drugs that suppresses sex hormones in adolescents by continually stimulating the pituitary gland. It will now…
